Wei Chen – InmunoES

Mapping the genetic–transcriptional landscape of thyroid irAEs in sintilimab therapy: toward biomarker-guided immunotoxicity prediction

27 de October de 2025 by Wei Chen

ObjectiveBy integrating whole-genome resequencing (WGR) with longitudinal transcriptomic profiling, this study aimed to unravel the genetic–transcriptional regulatory network underlying thyroid immune-related adverse events (irAEs) in non-small cell lu…

Bispecific antibody for lung cancer: mechanisms and clinical insights

29 de May de 2025 by Wei Chen

Lung cancer is a refractory malignancy. Although various therapeutic options, including targeted therapies, immune checkpoint inhibitors, and systemic chemotherapy, have significantly improved the prognosis of lung cancer patients, five-year survival r…

Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores

10 de July de 2024 by Wei Chen

IntroductionThe systematic review and network meta-analysis (NMA) consolidate all relevant randomized controlled trials (RCTs) related to initial immunotherapy treatments for advanced esophageal squamous cell carcinoma (ESCC). Our goal is to thoroughly…